 been reported from 9.2% to
26%. However, this reï¬‚ects patient heterogeneity and
lack of standard selection criteria for intervention.350
The lack of high-quality data in the treatment of stroke
in evolution precludes any clear conclusions regarding
management of these patients. However, many extrapolate data for improved results with early CEA for stroke
because these patient populations may overlap.
Crescendo TIA. Patients with crescendo TIAs